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Abstract
The debates continue over the validity of the metabolic syndrome concept. The continuous increment of the
obesity pandemic is almost worldwide paralleled by rising rates of metabolic syndrome prevalence. Then, it seems
obvious that these debates drove the need for further investigations as well as a deeper cooperation between
relevant national and international organizations regarding the issue. Instead, part of the scientific community
elected to totally “dismiss” the concept of the metabolic syndrome. Meanwhile, the best available evidence from
three consecutive large meta-analyses has systematically shown that people with metabolic syndrome are at
increased risk of cardiovascular events. The most recent and largest of them included near one million patients
(total n = 951,083). The investigators concluded that the metabolic syndrome is associated with a 2-fold increase in
cardiovascular outcomes and a 1.5-fold increase in all-cause mortality rates. One of the ways to hit the metabolic
syndrome is an utterly simplistic view on this concept as a predictive tool only. Of course, the presence of the
metabolic syndrome possesses a definite predictive value, but first of all it is a widely accepted concept regarding
a biological condition based on the complex and interrelated pathophysiological mechanisms starting from excess
central adiposity and insulin resistance. Therefore, it is completely unfair to compare it with statistically constructed
predictive tools, including stronger prognostic variables even unrelated to each other from the biological point of
view. For example, in the criteria for metabolic syndrome (in contrast to Framingham score) age and cholesterol -
presumably low density lipoprotein - cholesterol (LDL-C) - levels are not included, as well as a variety of strong
predictors used in other risk-stratification scores: previous myocardial infarction, heart failure, smoking, family
history, etc. However, the metabolic syndrome identifies additional important residual vascular risk mainly
associated with insulin resistance and atherogenic dyslipidemia (low high density lipoprotein-cholesterol (HDL-C),
high triglycerides, small, dense LDL-C). Therefore, the metabolic syndrome could be a useful additional contributor
in estimation of global cardiovascular risk beyond age, high LDL-C or other standard risk factors. The components
of the metabolic syndrome have partially overlapping mechanisms of pathogenic actions mediated through
common metabolic pathways. Therefore their total combined effect could be less than the summed of the
individual effects. The concept that the metabolic syndrome is a consequence of obesity and insulin resistance,
provides a useful “life-style changes” approach for prevention and treatment: caloric restriction, weight-loss and
increased physical activity. The next step could theoretically be pharmacological interventions such as metformin,
acarbose, fibrates, weight-loss drugs (currently only orlistat is practically available) and perhaps glucagon-like
peptide-1 agonists. A third step should probably be kept for bariatric surgery.
The diagnostic criteria for the metabolic syndrome are
not ideal. Controversy continues over the validity of its
naming, as well as disagreement over its relevance as a
practical clinical tool. One of the important questions
which still remain open is its predictive value: does the
metabolic syndrome forecast cardiovascular events,
diabetes or disease progression any better than the sum
of its components?
The continuous increment of the obesity pandemic is
almost worldwide paralleled by rising rates of metabolic
syndrome prevalence. Then, it seems obvious that these
debates drove the need for further investigations as well as
a deeper cooperation between relevant national and inter-
national organizations aiming to improve and unify the
terms [1,2]. Surprisingly, part of the scientific community
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syndrome instead [3-5].
Meanwhile, the best available evidence from three
consecutive large meta-analyses systematically had
shown that people with metabolic syndrome are at
increased risk of cardiovascular events [6-8]. The most
recent and largest of them [8] included near one million
patients (total n = 951,083). The investigators concluded
that the metabolic syndrome is associated with a 2-fold
increase in cardiovascular outcomes and a 1.5-fold
increase in all-cause mortality rates. The meta-analysis
showed that the point estimates for cardiovascular risk
were consistently higher in women vs. men. A very
important finding of this study demonstrated that cardi-
ovascular risk was still high in patients with the meta-
bolic syndrome but without diabetes.
The prognostic importance of the metabolic syndrome,
compared with that of the sum of its individual compo-
nents has repeatedly been challenged [5,9,10]. For exam-
ple, in a cohort study of 2,815 patients [9], the risk of
cardiovascular disease (CVD) mortality associated with the
metabolic syndrome (HR: 2.53; 95% CI: 1.74 to 3.67) was
similar to the risk associated with impaired fasting glucose
(HR: 2.87; 95% CI: 1.96 to 4.20). However, it seems that
most of the published reports indicate that the syndrome
predicts cardiovascular events or/and diabetes indepen-
dently from other conventional risk factors [11-16]. Our
group has shown that metabolic syndrome is a strong
independent predictor of mortality and morbidity in
patients with acute coronary syndrome [16]. It should be
specifically pointed out that patients with hyperglycemia
and metabolic syndrome had higher mortality rates com-
pared with patients with the same hyperglycemia but with-
out metabolic syndrome (for example 30-day mortality
rates respectively 8.3% vs. 2.5%, p <0.05)!
This situation resembled the old and long- lasting dis-
cussion regarding clinical significance of insulin resis-
tance: over the past years it has been recognized that
insulin resistance is an independent risk factor for the
development of type 2 diabetes mellitus, whereas its
association with major cardiovascular events remained
controversial. We have previously demonstrated the
independent association of insulin resistance with major
cardiovascular events and mortality [17]. After multi-
variable adjustments, measurable effect of insulin resis-
tance was somewhat attenuated but remained
significant. Similarly, insulin resistance was associated
with >2-fold increased age-adjusted risk for the develop-
ment of diabetes in nondiabetic subjects. After adjust-
ment for multiple potential confounders, the prediction
conferred by the insulin resistance for new diabetes was
substantially attenuated, mainly after inclusion of body
mass index in the model, remaining yet strongly signifi-
cant. Consequently, insulin resistance and body mass
index are most likely associated with diabetes develop-
ment by partially (but not completely) reciprocated
mechanisms.
One of the ways to hit the metabolic syndrome is an
utterly simplistic view on this concept as a predictive
tool only. Of course, the presence of the metabolic syn-
drome possesses a definite predictive value, but first of
all it is a widely accepted concept regarding a biological
condition based on the complex and interrelated patho-
physiological mechanisms starting from excess central
adiposity and insulin resistance. Therefore, it is comple-
tely unfair to compare it with statistically constructed
predictive tools, including stronger prognostic variables
even unrelated to each other from the biological point
of view. For example, in the criteria for metabolic syn-
drome (in contrast to Framingham score) age and cho-
lesterol (presumably LDL-C) levels are not included, as
well as a variety of strong predictors used in other risk-
stratification scores: previous myocardial infarction,
heart failure, smoking, family history, etc. However, the
metabolic syndrome identifies additional important resi-
dual vascular risk mainly associated with insulin resis-
tance and atherogenic dyslipidemia (low HDL-C, high
triglycerides, small dense LDL-C). Therefore, the meta-
bolic syndrome could be a useful additional contributor
in estimation of global cardiovascular risk beyond age,
high LDL-C or other standard risk factors.
Moreover, even critics of the metabolic syndrome con-
cept should agree that obesity, dysglycemia, dyslipidemia
and hypertension coexist more frequently than predicted
by chance. These common chronic conditions (and
components of the metabolic syndrome) have partially
overlapping mechanisms of pathogenic actions mediated
through common metabolic pathways. Therefore their
total combined effect could be less than the summed of
the individual effects.
People with the metabolic syndrome usually pass
through the phases of excessive adipogenesis (obesity),
nuclear peroxisome proliferator-activated (PPAR) recep-
tors modulation, insulin resistance, hyperinsulinemia,
impaired glucose postprandial and fasting levels
[2,18-22]. Fasting glucose is presumed to remain normal
or borderline as long as insulin hypersecretion can com-
pensate for insulin resistance. The fall in insulin secre-
tion (due to pancreatic beta cells stress and damage)
leading to hyperglycemia occurs as a late phenomenon
and, in fact, separates the patients with metabolic syn-
drome from those with or without overt diabetes.
Development of insulin resistance in consequence of
excess central adiposity has been considered to be key
event in the origin and progression of the metabolic
syndrome. It represents a complex interaction of mala-
daptive characteristics related to impaired insulin action
at target organs and external factors such as genetics
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that underlie insulin resistance (mediated in part via
nuclear PPAR) contribute for many of the clinical com-
ponents of the metabolic syndrome, although the precise
associations remain still weakly understood [2,21,23-26].
Emerging multiple areas of metabolic syndrome
research interests include nowadays heterogeneous
topics like as adiponectin, angiotensinogen, resistin, and
leptin secretion [27-29], nonalcoholic fatty liver disease
and liver steatosis [30-32], hyperuricemia [33], genetic
predisposition [34,35]; the role of inflammation, inter-
leukins and high-sensitivity C-reactive protein [36-39];
age and gender specific profiles [40,41], the possible
ways for treatment optimization [42-47] and several
additional matters.
The concept that the metabolic syndrome is a conse-
quence of obesity and insulin resistance, provides a use-
ful “life-style changes” approach for prevention and
treatment: caloric restriction, weight-loss and increased
physical activity. The next step could theoretically be
pharmacological interventions such as metformin, acar-
bose, fibrates, weight-loss drugs (currently only orlistat
is practically available) and perhaps glucagon-like pep-
tide-1 agonists [48-52]. A third step should probably be
kept for bariatric surgery [53,54].
In conclusion, currently available evidences strongly
support the evolving concept of the metabolic syndrome
as an important clustering of the cardiovascular risk fac-
tors and diabetes. Resembling Mark Twain’sr e n o w n e d
saying [55], the reports of its death are an exaggeration.
The recognition, prevention, and treatment of the meta-
bolic syndrome and its underlying risk factors should
become an important approach for the reduction of car-
diovascular disease burden in the general population.
However, future problem-oriented research is needed to
improve and unify the diagnostic criteria for the syn-
drome, its genetic and environmental basis and the opti-
mal medical management.
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